Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging

Summary

This is a two-tiered pilot study in which there will be no randomization and no placebo treatment. This study will be to perform metabolic magnetic resonance imaging on men suspected to have a prostate cancer to understand if metabolic MRI can be safely performed on this population

Eligibility

Inclusion Criteria:

1. Age greater than 40 and less than 80 years
2. Clinical suspicion or history of prostate cancer reflected by one of the following:

   * PSA \> 4ng/ml
   * Abnormal DRE exam
   * Known tissue diagnosis of prostate cancer from prior workup
3. Patient planning to undergo either a MRI targeted biopsy or radical prostatectomy for prostate cancer workup or treatment

Exclusion Criteria:

1. Inability to undergo MRI scan
2. Inability to receive IV contrast as per institutional protocol.

Conditions2

Interventions1

Locations1 site

Find trials near these locations

Related trials

• Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body — National Heart Centre Singapore
• Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial Metastasis Treated With (SRS) — Sunnybrook Health Sciences Centre
• Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors — Robert Bok, MD, PhD
• Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer — University of California, San Francisco
• Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors — University of California, San Francisco
• Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer — Ivan de Kouchkovsky, MD
• HP Pyruvate MRI in Cancers — University of Maryland, Baltimore
• Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas — University of Maryland, Baltimore

Browse More Trials